On flattening filter-free portal dosimetry

Rapid in vivo EPID image prediction using a combination of analytically calculated attenuation and AI predicted scatter

BACKGROUND

The electronic portal imaging device (EPID) can be used in vivo, to detect on-treatment errors by evaluating radiation exiting a patient. To detect deviations from the planning intent, image predictions need to be modeled based on the patient's anatomy and plan information. To date in vivo transit images have been predicted using Monte Carlo (MC) algorithms. A deep learning approach can make predictions faster than MC and only requires patient information for training.

PURPOSE

To test the feasibility and reliability of creating a deep-learning model with patient data for predicting in vivo EPID images for IMRT treatments.

METHODS

In our approach, the in vivo EPID image was separated into contributions from primary and scattered photons. A primary photon attenuation function was determined by measuring attenuation factors for various thicknesses of solid water. The scatter component of in vivo EPID images was estimated using a convolutional neural network (CNN). The CNN input was a 3-channel image comprised of the non-transit EPID image and ray tracing projections through a pretreatment CBCT. The predicted scatter component was added to the primary attenuation component to give the full predicted in vivo EPID image. We acquired 193 IMRT fields/images from 93 patients treated on the Varian Halcyon. Model training:validation:test dataset ratios were 133:20:40 images. Additional patient plans were delivered to anthropomorphic phantoms, yielding 75 images for further validation. We assessed model accuracy by comparing model-calculated and measured in vivo images with a gamma comparison.

RESULTS

Comparing the model-calculated and measured in vivo images gives a mean gamma pass rate for the training:validation:test datasets of 95.4%:94.1%:92.9% for 3%/3 mm and 98.4%:98.4%:96.8% for 5%/3 mm. For images delivered to phantom data sets the average gamma pass rate was 96.4% (3%/3 mm criteria). In all data sets, the lower passing rates of some images were due to CBCT artifacts and patient motion that occurred between the time of CBCT and treatment.  CONCLUSIONS: The developed deep-learning-based model can generate in vivo EPID images with a mean gamma pass rate greater than 92% (3%/3 mm criteria). This approach provides an alternative to MC prediction algorithms. Image predictions can be made in 30 ms on a standard GPU. In future work, image predictions from this model can be used to detect in vivo treatment errors and on-treatment changes in patient anatomy, providing an additional layer of patient-specific quality assurance.

Commissioning and clinical evaluation of a novel high-resolution quality assurance digital detector array for SRS and SBRT

PURPOSE

We aimed to perform the commissioning and clinical evaluation of myQA SRS detector array for patient-specific quality assurance (PSQA) of stereotactic radiosurgery (SRS)/ stereotactic body radiotherapy (SBRT) plans.

METHODS

To perform the commissioning of myQA SRS, its dose linearity, dose-rate dependence, angular dependence, and field-size dependence were investigated. Ten SBRT plans were selected for clinical evaluation: 1) Common clinical deviations based on the original SBRT plan (Plan0), including multileaf collimator (MLC) positioning deviation and treatment positioning deviation were introduced. 2) Compared the performance of the myQA SRS and a high-resolution EPID dosimetry system in PSQA measurement for the SBRT plans. Evaluation parameters include gamma passing rate (GPR) and distance-to-agreement (DTA) pass rate (DPR).

RESULTS

The dose linearity, angle dependence, and field-size dependence of myQA SRS system exhibit excellent performance. The myQA SRS is highly sensitive in the detection of MLC deviations. The GPR of (3%/1 mm) decreases from 90.4% of the original plan to 72.7%/62.9% with an MLC outward/inward deviation of 3 mm. Additionally, when the setup error deviates by 1 mm in the X, Y, and Z directions with the GPR of (3%/1 mm) decreasing by an average of -20.9%, -25.7%, and -24.7%, respectively, and DPR (1 mm) decreasing by an average of -33.7%, -32.9%, and -29.8%. Additionally, the myQA SRS has a slightly higher GPR than EPID for PSQA, However, the difference is not statistically significant with the GPR of (3%/1 mm) of (average 90.4%% vs. 90.1%, p = 0.414).

CONCLUSION

Dosimetry characteristics of the myQA SRS device meets the accuracy and sensitivity requirement of PSQA for SRS/SBRT treatment. The dose rate dependence should be adequately calibrated before its application and a more stringent GPR (3%/1 mm) evaluation criterion is suggested when it is used for SRS/SBRT QA.

Evaluation of a Scintillating Plastic Optical Fiber Device for Measuring kV-Cone Beam Computed Tomography Dose

BACKGROUND

Justification of imaging procedures such as cone beam computed tomography (CBCT) in radiotherapy makes no doubt. However, the CBCT composite dose is rarely reported or optimized, even though the repeated CBCT cumulative dose can be up to 3% of the prescription dose. This study aimed to evaluate the performance and utility of a new plastic scintillating optical fiber dosimeter for CBCT dosimetric quality assurance (QA) applications before a potential application in patient composite CBCT dosimetry.

METHODS

The dosimeter, made of 1 mm diameter plastic fiber, was installed under a linear accelerator treatment table and linked to photodetectors. The fiber impact on the fluence and dose delivered was respectively assessed with an electronic portal imaging device (EPID) and EBT3 Gafchromic® film. The presence of artifacts was visually evaluated on kV images. The dosimeter performances were determined for various acquisition parameters by comparison with ionization chamber values.

RESULTS

The maximum impact of the fiber on the fluence measured by the EPID was -1.2% for the 6 MV flattening filter-free beam. However, the fiber did not alter the film dose profile when measured for all the beams tested. The fiber was not visible at energies ≥ 80 kV and was merely visible on the CBCT images. When the rate of images per second or mA was changed, the maximum relative difference between the device and the ionization chamber CTDIs was <5%. Changing collimation led to a -7.2% maximum relative difference with an absolute dose difference that was insignificant (-0.3 mGy). Changing kV was associated with a -8.7% maximum relative difference, as published in the literature.

CONCLUSIONS

The dosimeter may be a promising device for CBCT recurrent dosimetry quality control or dose optimization. According to these results, further developments are in progress in order to adapt the solution to the measurement of patient composite CBCT doses.

AAPM Task Group Report 307: Use of EPIDs for Patient-Specific IMRT and VMAT QA

PURPOSE

Electronic portal imaging devices (EPIDs) have been widely utilized for patient-specific quality assurance (PSQA) and their use for transit dosimetry applications is emerging. Yet there are no specific guidelines on the potential uses, limitations, and correct utilization of EPIDs for these purposes. The American Association of Physicists in Medicine (AAPM) Task Group 307 (TG-307) provides a comprehensive review of the physics, modeling, algorithms and clinical experience with EPID-based pre-treatment and transit dosimetry techniques. This review also includes the limitations and challenges in the clinical implementation of EPIDs, including recommendations for commissioning, calibration and validation, routine QA, tolerance levels for gamma analysis and risk-based analysis.

METHODS

Characteristics of the currently available EPID systems and EPID-based PSQA techniques are reviewed. The details of the physics, modeling, and algorithms for both pre-treatment and transit dosimetry methods are discussed, including clinical experience with different EPID dosimetry systems. Commissioning, calibration, and validation, tolerance levels and recommended tests, are reviewed, and analyzed. Risk-based analysis for EPID dosimetry is also addressed.

RESULTS

Clinical experience, commissioning methods and tolerances for EPID-based PSQA system are described for pre-treatment and transit dosimetry applications. The sensitivity, specificity, and clinical results for EPID dosimetry techniques are presented as well as examples of patient-related and machine-related error detection by these dosimetry solutions. Limitations and challenges in clinical implementation of EPIDs for dosimetric purposes are discussed and acceptance and rejection criteria are outlined. Potential causes of and evaluations of pre-treatment and transit dosimetry failures are discussed. Guidelines and recommendations developed in this report are based on the extensive published data on EPID QA along with the clinical experience of the TG-307 members.

CONCLUSION

TG-307 focused on the commercially available EPID-based dosimetric tools and provides guidance for medical physicists in the clinical implementation of EPID-based patient-specific pre-treatment and transit dosimetry QA solutions including intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) treatments.

Verification of an optimizer algorithm by the beam delivery evaluation of intensity-modulated arc therapy plans

Background

In the case of dynamic radiotherapy plans, the fractionation schemes can have dosimetric effects. Our goal was to define the effect of the fraction dose on the plan quality and the beam delivery.

Materials and methods

Treatment plans were created for 5 early-stage lung cancer patients with different dose schedules. The planned total dose was 60 Gy, fraction dose was 2 Gy, 3 Gy, 5 Gy, 12 Gy and 20 Gy. Additionally renormalized plans were created by changing the prescribed fraction dose after optimization. The dosimetric parameters and the beam delivery parameters were collected to define the plan quality and the complexity of the treatment plans. The accuracy of dose delivery was verified with dose measurements using electronic portal imaging device (EPID).

Results

The plan quality was independent from the used fractionation scheme. The fraction dose could be changed safely after the optimization, the delivery accuracy of the treatment plans with changed prescribed dose was not lower. According to EPID based measurements, the high fraction dose and dose rate caused the saturation of the detector, which lowered the gamma passing rate. The aperture complexity score, the gantry speed and the dose rate changes were not predicting factors for the gamma passing rate values.

Conclusions

The plan quality and the delivery accuracy are independent from the fraction dose, moreover the fraction dose can be changed safely after the dose optimization. The saturation effect of the EPID has to be considered when the action limits of the quality assurance system are defined.

Planar EPID-Based Dosimetry for SRS and SRT Patient-Specific QA

The study’s purpose was to develop and validate Electronic Portal Imaging Device (EPID)-based dosimetry for Stereotactic Radiosurgery (SRS) and Stereotactic Radiation Therapy (SRT) patient-specific Quality Assurance (QA). The co-operation between extended Source-to-Imager Distance (SID) to reduce the saturation effect and simplify the EPID-based dosimetry model was used to perform patient-specific QA in SRS and SRT plans. The four parameters were included for converting the image to dose at depth 10 cm; dose-response linearity with MU, beam profile correction, collimator scatter and water kernel. The model accuracy was validated with 10 SRS/SRT plans. The traditional diode arrays with MapCHECK were also used to perform patient-specific QA for assuring model accuracy. The 150 cm-SID was found a possibility to reduce the saturation effect. The result of model accuracy was found good agreement between our EPID-based dosimetry and TPS calculation with GPR more than 98% for gamma criteria of 3%/3 mm, more than 95% for gamma criteria of 2%/2 mm, and the results related to the measurement with MapCHECK. This study demonstrated the method to perform SRT and SRT patient-specific QA using EPID-based dosimetry in the FFF beam by co-operating between the extended SID that can reduce the saturation effect and estimate the planar dose distribution with the in-house model.

EPID-based 3D dosimetry for pre-treatment FFF VMAT stereotactic body radiotherapy plan verification using dosimetry CheckTM

PURPOSE

The software Dosimetry Check (DC) reconstructs the 3D dose distribution on CT images data set by using EPID measured signal. This study aimed to evaluate DC for stereotactic body radiotherapy (SBRT) with unflattened photon beams (FFF) for dosimetric independent plan verification in pre-treatment modality.

METHODS

DC v.4.1 was configured for Varian TrueBeam STx FFF beams equipped with EPID aS-1200. The DC FFF models were tested using arc open fields (from 1×1 cm² to 15×15 cm²) and VMAT (Volumetric Modulated Arc Therapy) SBRT plans on phantom and patient CTs. DC dose distributions (D_DC) were compared with that calculated by Eclipse with Acuros XB algorithm (D_AXB) and one measured by Octavius 1000 SRS detector (D_OCT). All differences were quantified in terms of the local 3D gamma passing rate (%GP), DVH and point dose differences.

RESULTS

DC was configured for FFF VMAT using an appropriate correction procedure. %GP_2%2mm (mean±standard deviation) of D_OCT-D_DC was 96.3±2.7% for open fields whereas it was 90.1±5.9% for plans on homogeneous phantom CT. However, average %GP_3%3mm of D_AXB-D_DC was 95.0±4.1 for treatments on patient CT. The fraction of plans passing the %GP_3%3mm DQA tolerance level [10% (50%) of maximum dose threshold] were 20/20 (14/20) and 18/20 (16/20) for OCT on phantom CT and DC on patient CT, respectively.

CONCLUSIONS

DC characterization for FFF beams was performed. For stereotactic VMAT plan verifications DC showed good agreement with TPS whereas underlined discrepancies with Octavius in the high dose regions. A customized tolerance level is required for EPID-based VMAT FFF pre-treatment verification when DC system is applied.

Dosimetric performance of continuous EPID imaging in stereotactic treatment conditions

PURPOSE

This study aims at investigating the dosimetric characteristics of a Varian aS1000 EPID, focusing on its continuous acquisition mode under the challenging conditions that can be met in stereotactic radiotherapy verification.

METHODS

An aS1000 EPID installed on a Varian TrueBeamSTx was irradiated with 6 and 10 MV unflattened and flattened photon beams. In order to avoid detector saturation, the source-to-detector distance (SDD) was set to 150 or 180 cm depending on the dose rate. EPID image sets were acquired in continuous mode (CM) and also in the commonly used integrated mode (IM) for comparison, to evaluate dose linearity (including dose rate dependence), repeatability, reproducibility, stability, ghosting effect and field size dependence.

RESULTS

CM response linearity was found to be within 0.8% of IM and independent of dose rate. Response repeatability was slightly better for IM and FF beams, being in all cases within 0.9%. Reproducibility was within 0.6% for both modes and all beam qualities. Response stability between continuous frames varied within 1% for dynamic and static irradiations and for all the beam qualities, showing its independence from these parameters. Ghosting effect was not significant, being comparable to signal variations between continuous frames (±1%). Field size dependence in both modes agreed within 1%.

CONCLUSIONS

The dosimetric response of the aS1000 EPID in CM with FFF beams and high dose rates is comparable to that in IM and for flattened beams provided that the appropriate SDD is used. aS1000 EPID in continuous acquisition mode is therefore suitable for stereotactic applications.

Dosimetric Validation of Digital Megavolt Imager for Flattening Filter Free Beams in the Pre-Treatment Quality Assurance of Stereotactic Body Radiation Therapy for Liver Metastases

Aim:

The aim is to evaluate the use of digital megavolt imager (DMI) aS1200 in portal dosimetry with flattening filter free (FFF) beams.

Materials and Methods:

Dosimetric properties of DMI is characterized at 6MV FFF beams for signal saturation, dose linearity, dependency on dose-rate and source-detector distance (SDD), signal lag (ghosting), and back scatter. Portal dosimetry is done for twenty volumetric modulated arc therapy (VMAT) based stereotactic body radiotherapy (SBRT) plans for the treatment of liver metastases and the results are compared with repeated measurements of Octavius 4D.

Results:

The detector signal to monitor unit (MU) ratio drops drastically below 25MU. The detector linearity with dose is within 1% and no evidence of signal saturation as such. The aS1200 response variation across various dose rates and SDD is <0.4% and <0.2% respectively. The effect of ghosting increased distinctly at higher dose rate but however it is negligible (0.1%). The impact of back scatter is <0.3% because of additional shielding provided at the back of the detector. The portal dosimetry results of SBRT QA plans evaluated at the gamma criteria of 2mm/2% (DTA/DD) both under global and local mode analysis has shown an average gamma passing rate of area gamma (<1) 97.9±0.8% and 96.4±0.9%. The SBRT QA results observed in aS1200 are inline and consistent with Octavius 4D measured results.

Conclusion:

The characteristics of aS1200 evaluated at FFF beams have shown its potential ability as QA tool and can be used in SBRT QA for liver metastases with greater confidence.

Early clinical experience with varian halcyon V2 linear accelerator: Dual-isocenter IMRT planning and delivery with portal dosimetry for gynecological cancer treatments

PURPOSE

Varian Halcyon linear accelerator version 2 (The Halcyon 2.0) was recently released with new upgraded features. The aim of this study was to report our clinical experience with Halcyon 2.0 for a dual-isocenter intensity-modulated radiation therapy (IMRT) planning and delivery for gynecological cancer patients and examine the feasibility of in vivo portal dosimetry.

METHODS

Twelve gynecological cancer patients were treated with extended-field IMRT technique using two isocenters on Halcyon 2.0 to treat pelvis and pelvic/or para-aortic nodes region. The prescription dose was 45 Gy in 25 fractions (fxs) with simultaneous integrated boost (SIB) dose of 55 or 57.5 Gy in 25 fxs to involved nodes. All treatment plans, pretreatment patient-specific QA and treatment delivery records including daily in vivo portal dosimetry were retrospectively reviewed. For in vivo daily portal dosimetry analysis, each fraction was compared to the reference baseline (1st fraction) using gamma analysis criteria of 4 %/4 mm with 90% of total pixels in the portal image planar dose.

RESULTS

All 12 extended-field IMRT plans met the planning criteria and delivered as planned (a total of 300 fractions). Conformity Index (CI) for the primary target was achieved with the range of 0.99-1.14. For organs at risks, most were well within the dose volume criteria. Treatment delivery time was from 5.0 to 6.5 min. Interfractional in vivo dose variation exceeded gamma analysis threshold for 8 fractions out of total 300 (2.7%). These eight fractions were found to have a relatively large difference in small bowel filling and SSD change at the isocenter compared to the baseline.

CONCLUSION

Halcyon 2.0 is effective to create complex extended-field IMRT plans using two isocenters with efficient delivery. Also Halcyon in vivo dosimetry is feasible for daily treatment monitoring for organ motion, internal or external anatomy, and body weight which could further lead to adaptive radiation therapy.

Impact of plan parameters and modulation indices on patient-specific QA results for standard and stereotactic VMAT

PURPOSE

To demonstrate the impact of modulation indices and plan parameters on the gamma passing rates (GPR) of patient-specific quality assurance of standard and stereotactic volumetric modulated arc therapy (VMAT) plans.

METHODS

A total of 758 patients' QA plans were utilized, including standard VMAT plans with Trilogy (n = 87, group A) and TreuBeam STx (n = 332, group B), and 339 stereotactic VMAT plans with TrueBeam STx (group C). Modulation indices were obtained considering the speed and acceleration of the multileaf collimator (MLC) (MI_s, MI_a), and MLC, gantry speed, and dose rate changes (MI_t). The mean aperture size (MA), monitor unit (MU), and amount of jaw tracking (%JT) were acquired. Gamma analysis was performed with 2 mm/2% and 1 mm/2% for the standard and stereotactic VMAT plans, respectively. Statistical analyses were performed to investigate the correlation between modulation index/plan parameters and GPR.

RESULTS

Spearman's rank correlation to GPRs with MI_s, MI_a, and MI_t, were -0.44, -0.45, and -0.46 for group A; -0.39, -0.37, and -0.38 for group B; and -0.04, -0.11, and -0.10 for group C, respectively. While MU and MA showed significant correlations in all groups, %JT showed a significant correlation only with stereotactic VMAT plans. The most influential parameter combinations were MU-MA (r_s = 0.50), MI_s-%JT (r_s = 0.43), and MU-%JT (r_s = 0.38) for groups A, B, and C, respectively.

CONCLUSIONS

MLC modulation mostly affected the GPR in the delivery of standard VMAT plans, while MU and %JT showed more importance in stereotactic VMAT plans.

Dose rate response of Digital Megavolt Imager detector for flattening filter-free beams

In this study we investigated the dose rate response characteristics of the Digital Megavolt Imager (DMI) detector, including panel saturation, linearity, and imager ghosting effects for flattening filter‐free (FFF) beams. The DMI detector dose rate response characteristics were measured as a function of dose rate on a Varian TrueBeam machine. Images were acquired at dose rates ranging from 400 to 1400 MU/min for 6XFFF and 400 to 2400 MU/min for 10XFFF. Line profiles and central portal doses derived from the images were analyzed and compared. The linearity was verified by acquiring images with incremental Monitor Unit (MU) ranging from 5 to 500 MU. Ghosting effects were studied at different dose rates. Finally, for validation, test plans with optimal fluence were created and measured with different dose rates. All test plans were analyzed with a Gamma criteria of 3%‐3 mm and 10% dose threshold. Our study showed that there was no panel saturation observed from the profile comparison even at the maximum dose rate of 2400 MU/min. The central portal doses showed a slight decrease (1.013–1.008 cGy/MU for 6XFFF, and 1.020–1.009 cGy/MU for 10XFFF) when dose rate increased (400–1400 MU/min for 6XFFF, and 400–2400 MU/min for 10XFFF). The linearity of the DMI detector response was better than 0.5% in the range of 20–500 MU for all energies. The residual image was extremely small and statistically undetectable. The Gamma index measured with the test plans decreased from 100% to 97.8% for 6XFFF when dose rate increased from 400 to 1400 MU/min. For 10XFFF, the Gamma index decreased from 99.9% to 91.5% when dose rate increased from 400 to 2400 MU/min. We concluded that the Portal Dosimetry system for the TrueBeam using DMI detector can be reliably used for IMRT and VMAT QA for FFF energies.